Selumetinib was a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor for treatment of neurofibromatosis, pediatric low-grade glioma, non-small cell lung cancer, and melanoma (Campagne et al., 2021). Here, MAP3K1 is linked to melanoma.